PTPRC and neoplasm: Lastly, a higher frequency of dying DiD+ tumor cells (but not CD45+ immune cells) was observed in mice receiving the combination therapy (Figure 4, C and F), indicating an increase of direct tumor cell lysis mediated by CDC.